Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bates

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 14, 2009
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt, Jeff Sperinde, Fanny Piette, et al.
The Journal of Infectious Diseases|September 9, 2006
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremiaPeter W Hunt, P Richard Harrigan, Wei Huang, et al.
Frontiers in Oncology|February 14, 2022
Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort StudyVittorio Fasulo, Marco Paciotti, Massimo Lazzeri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 28, 2022
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLCAileen I Fernandez, Niki Gavrielatou, Leena McCann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)Saranya Chumsri, Jeff Sperinde, Heshan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
The Lancet. Oncology|October 6, 2024
Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy studyDianna L Ng, Edda Vuhahula, Asteria H Kimambo, et al.
ACS Chemical Biology|July 26, 2023
Cellular Uptake of a Fluorescent Ligand Reveals Ghrelin <i>O</i>-Acyltransferase Interacts with Extracellular Peptides and Exhibits Unexpected Localization for a Secretory Pathway EnzymeMaria B Campaña, Tasha R Davis, Sadie X Novak, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
The Oncologist|January 12, 2012
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyRenata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|February 14, 2009
Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISHChristine Desmedt, Jeff Sperinde, Fanny Piette, et al.
The Journal of Infectious Diseases|September 9, 2006
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremiaPeter W Hunt, P Richard Harrigan, Wei Huang, et al.
Frontiers in Oncology|February 14, 2022
Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance" for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort StudyVittorio Fasulo, Marco Paciotti, Massimo Lazzeri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 28, 2022
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLCAileen I Fernandez, Niki Gavrielatou, Leena McCann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2018
High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)Saranya Chumsri, Jeff Sperinde, Heshan Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
The Lancet. Oncology|October 6, 2024
Xpert Breast Cancer STRAT4 Assay using fine-needle aspiration biopsy samples in a resource-constrained setting: a prospective diagnostic accuracy studyDianna L Ng, Edda Vuhahula, Asteria H Kimambo, et al.
ACS Chemical Biology|July 26, 2023
Cellular Uptake of a Fluorescent Ligand Reveals Ghrelin <i>O</i>-Acyltransferase Interacts with Extracellular Peptides and Exhibits Unexpected Localization for a Secretory Pathway EnzymeMaria B Campaña, Tasha R Davis, Sadie X Novak, et al.
Plos One|August 1, 2012
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerSae-Won Han, Yongjun Cha, Agnes Paquet, et al.
The Oncologist|January 12, 2012
Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyRenata Duchnowska, Wojciech Biernat, Barbara Szostakiewicz, et al.
Pageof 8